Bunya RNA 2: preclinical development

There is an enormous unmet medical need for therapies against cancer.  BunyaVax is using its RNA particle platform technology to develop novel cancer immunotherapies. They can be potentially applied as combination therapy together with other forms of immunotherapy or chemotherapy.

 

We have demonstrated that human dendritic cells infected with BunyaVax RNA particles can activate CD8+ T cells in vitro. Plus, we have shown that prophylactic and therapeutic vaccinations of mice with RNA particles encoding a single tumor-associated CD8 epitope can control the outgrowth of lymphoma cells in vivo. These results suggest that the system holds promise for cancer immunotherapy.

 

BunyaVax is currently developing specific RNA particles to enter into clinical trials.